Neurogene (NGNE)
38.60
+0.99 (2.63%)
Upcoming Events
Latest Headlines
Form SCHEDULE 13G/A Neurogene Inc. Filed by: Redmile Group, LLC
August 14, 2026 4:25 PM - SEC Filing
Form SCHEDULE 13G/A Neurogene Inc. Filed by: Trails Edge Capital Partners, LP
August 14, 2026 4:23 PM - SEC Filing
Form SCHEDULE 13G Neurogene Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
August 14, 2026 6:14 AM - SEC Filing
Neurogene (NGNE) PT Lowered to $65 at H.C. Wainwright
August 12, 2026 7:21 AM - StreetInsider
Neurogene (NGNE) PT Lowered to $166 at Canaccord
August 12, 2026 6:51 AM - StreetInsider
Form 10-Q Neurogene Inc. For: Jun 30
August 11, 2026 4:58 PM - SEC Filing
Neurogene (NGNE) Tops Q2 EPS by 38c
August 11, 2026 7:35 AM - StreetInsider
Form 8-K Neurogene Inc. For: Aug 11
August 11, 2026 7:33 AM - SEC Filing
Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates
August 11, 2026 7:30 AM - BizWire
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 4, 2026 4:01 PM - BizWire
Newleos Names Rohan Palekar as Board Chairman
July 28, 2026 7:00 AM - BizWire
Form 4 Neurogene Inc. For: Jul 06 Filed by: Cvijic Christine Mikail
July 7, 2026 9:08 PM - SEC Filing
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 6, 2026 4:01 PM - BizWire
Form 4 Neurogene Inc. For: Jul 01 Filed by: Cvijic Christine Mikail
July 2, 2026 6:43 PM - SEC Filing
Form 8-K Neurogene Inc. For: Jun 30
July 2, 2026 6:04 AM - SEC Filing
Form 424B5 Neurogene Inc.
July 2, 2026 6:04 AM - SEC Filing
Taysha Gene Therapies (TSHA) Reiterated at Market Outperform by Citizens
July 2, 2026 4:19 AM - StreetInsider
Neurogene (NGNE) PT Raised to $77 at Leerink
July 1, 2026 2:38 PM - StreetInsider
Neurogene prices $125 million public offering at $30 per share
July 1, 2026 7:00 AM - StreetInsider
Neurogene Inc. Announces Pricing of $125 Million Public Offering
July 1, 2026 7:00 AM - BizWire
Form 424B5 Neurogene Inc.
June 30, 2026 4:19 PM - SEC Filing
Neurogene launches public offering of common stock
June 30, 2026 4:01 PM - StreetInsider
Neurogene Inc. Announces Proposed Public Offering
June 30, 2026 4:01 PM - BizWire
Canaccord Reiterates Buy Rating on Neurogene (NGNE)
June 30, 2026 6:52 AM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Neurogene (NGNE)
June 30, 2026 6:45 AM - StreetInsider
Form 8-K Neurogene Inc. For: Jun 29
June 29, 2026 8:01 AM - SEC Filing
Neurogene reports Phase 1/2 gene therapy data for Rett syndrome
June 29, 2026 7:01 AM - StreetInsider
Neurogene Reports Positive Long-term Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome
June 29, 2026 7:00 AM - BizWire
Form 4/A Neurogene Inc. For: Jun 14 Filed by: Woods Keith
June 16, 2026 5:32 PM - SEC Filing
Form 4/A Neurogene Inc. For: Jan 16 Filed by: Woods Keith
June 16, 2026 5:32 PM - SEC Filing
Form 4/A Neurogene Inc. For: Jun 12 Filed by: Woods Keith
June 16, 2026 5:32 PM - SEC Filing
Form 3/A Neurogene Inc. For: Dec 18 Filed by: Woods Keith
June 16, 2026 5:30 PM - SEC Filing
H.C. Wainwright Reiterates Buy Rating on Neurogene (NGNE)
June 9, 2026 6:47 AM - StreetInsider
Full Article List
